In a powerful talk with Mathew Knowles and Courtney Bugler, CEO of Zero Prostate Cancer, we highlight the urgent need for awareness among Black men at risk.

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which ...

Several biomarker tests have been available for over a decade, with extensive research backing their effectiveness. Yet, many urologists remain unaware of their full potential to streamline practice ...

New research highlights the significance of timing and tumour location when evaluating PSMA PET scans following radiotherapy ...

On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer pre-chemotherapy. Just six days ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime.

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for use in patients with prostate cancer.

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals’ predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

As time goes by, the risk of prostate cancer among men is increasing. The World Health Organization (WHO) states that prostate cancer is the most common cancer in men after lung cancer. According to ...